VA Funds First Psychedelic-Assisted Therapy Study for Veterans Since the 1960s
• The Department of Veterans Affairs is funding a study on MDMA-assisted therapy for veterans with PTSD and alcohol use disorder, marking a significant shift in psychedelic research.
• The $1.5 million study, conducted with Brown and Yale universities, will assess the effectiveness and safety of MDMA in treating veterans with mental health issues.
• This initiative follows the FDA's previous rejection of MDMA-assisted therapy and aims to provide further scientific evidence on the potential benefits of psychedelics.
• Virginia Senate committee advances bill to fund clinical trials investigating the benefits of federally recognized breakthrough therapies for veterans’ mental health-related issues.
GE HealthCare's SIGNA MAGNUS Head-Only MRI System Receives FDA Clearance
• GE HealthCare's SIGNA MAGNUS, a 3.0T head-only MRI, has received FDA clearance, offering advanced neuroimaging capabilities for clinical and research use.
• The SIGNA MAGNUS features an innovative asymmetric gradient coil design, enhancing gradient performance and enabling high-resolution imaging with shorter scan times.
• This new MRI technology aims to improve the detection of neurological, oncological, and psychiatric conditions through advanced imaging and biomarker research.
• The system's HyperG gradient technology achieves high performance levels, improving spatial resolution and image clarity for more accurate diagnoses.
© Copyright 2025. All Rights Reserved by MedPath